Omega Therapeutics is a biopharmaceutical company that uses the OMEGA Epigenomic Programming platform to up-regulate the expression of HNF4a, control gene expression linked to cell-growth inhibition, down-regulate the CXCL1, 2, 3, and IL-8 gene cluster, reverse disease progression, inhibit hair growth, and treat lung cancer. The platform is designed to harness the power of epigenetics, the mechanism for gene control and cell differentiation, to restore liver-cell function in patients suffering from chronic liver diseases. The company was founded in 2016 and is based in Cambridge, Massachusetts.